Liposomal Lactoferrin as Potential Preventative and Cure for COVID-19
Author(s) -
Gabriel Serrano,
Iulia Kochergina,
Arturo Albors,
Eva Senra Díaz,
Mar Oroval,
Guillen Hueso,
Juan Monte Serrano
Publication year - 2020
Publication title -
international journal of research in health sciences
Language(s) - English
Resource type - Journals
ISSN - 2321-7251
DOI - 10.5530/ijrhs.8.1.3
Subject(s) - lactoferrin , covid-19 , medicine , virology , liposome , chemistry , infectious disease (medical specialty) , biochemistry , disease , outbreak
A prospective observational study was performed in 75 patients with typical symptoms of COVID-19 who tested positive to IgM/IgG rapid test. Patients were isolated and treated at home using remote systems, reviewed twice a day for 10 days, and followed up to 1 month. A liposomal bovine lactoferrin (LLF) nutritional syrup food supplement (32 mg of LF/10 ml plus 12 mg of vitamin C) was administered orally in 4 to 6 doses per day for 10 days. In addition, a zinc solution was administered at the dose of 10 mg/10 ml twice or three times a day. A control group of 12 patients who took only LLF was included. All family members in contact with patients (256 persons) were also treated with half of this dose. The treatment allowed a complete and fast recovery in all patients (100%) within the first 4-5 days. Same treatment at lower dose prevented the disease in healthy persons directly related with the affected patients. Weakness (95%) followed by a dysfunction in the perception of smelling and tasting (88%), cough (83%), muscular pain (67%) were the most frequent complains. LF possess antiviral, immunomodulatory and anti-inflammatory effects which might be important for the treatment of COVID-19 infection. We conclude that LLF potentially prevent and cure COVID 19 infection. ©2020 Serrano G. This is an open-access article distributed under the terms of the Creative Commons Attribution (CCBY 4.0), which permits unrestricted use, distribu-tion, and reproduction in any medium, provided the original author and source are credited Gabriel Serrano1,*, Iulia Kochergina1, Arturo Albors2, Eva Diaz3, Mar Oroval3, Guillen Hueso3, Juan M Serrano3 1Dr. Serrano Dermatology Clinic, Valencia, Spain 2Medical Department of Sesderma Laboratories, Valencia, Spain 3Research Department of Sesderma Laboratories, Valencia, Spain Corresponding author: Dr. Gabriel Serrano Dr. Serrano Dermatology Clinic, Valencia, Spain. E-mail: gabriels@sesderma.com DOI: 10.5530/ijrhs.8.1.3 Received: 07-04-2020; Accepted: 20-04-2020; Published: 22-04-2020.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom